A shotgun metagenomic analysis of the fecal microbiome in humans infected with Giardia duodenalis.


Journal

Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774

Informations de publication

Date de publication:
18 Jul 2023
Historique:
received: 10 04 2023
accepted: 28 05 2023
medline: 21 7 2023
pubmed: 19 7 2023
entrez: 18 7 2023
Statut: epublish

Résumé

The mechanisms underlying the clinical outcome disparity during human infection with Giardia duodenalis are still unclear. In recent years, evidence has pointed to the roles of host factors as well as parasite's genetic heterogeneity as major contributing factors in the development of symptomatic human giardiasis. However, it remains contested as to how only a small fraction of individuals infected with G. duodenalis develop clinical gastrointestinal manifestations, whereas the majority of infected individuals remain asymptomatic. Here, we demonstrate that diversity in the fecal microbiome correlates with the clinical outcome of human giardiasis. The genetic heterogeneity of G. duodenalis clinical isolates from human subjects with asymptomatic and symptomatic giardiasis was determined using a multilocus analysis approach. We also assessed the genetic proximity of G. duodenalis isolates by constructing phylogenetic trees using the maximum likelihood. Total genomic DNA (gDNA) from fecal specimens was utilized to construct DNA libraries, followed by performing paired-end sequencing using the HiSeq X platform. The Kraken2-generated, filtered FASTQ files were assigned to microbial metabolic pathways and functions using HUMAnN 3.04 and the UniRef90 diamond annotated full reference database (version 201901b). Results from HUMAnN for each sample were evaluated for differences among the biological groups using the Kruskal-Wallis non-parametric test with a post hoc Dunn test. We found that a total of 8/11 (72.73%) human subjects were infected with assemblage A (sub-assemblage AII) of G. duodenalis, whereas 3/11 (27.27%) human subjects in the current study were infected with assemblage B of the parasite. We also found that the parasite's genetic diversity was not associated with the clinical outcome of the infection. Further phylogenetic analysis based on the tpi and gdh loci indicated that those clinical isolates belonging to assemblage A of G. duodenalis subjects clustered compactly together in a monophyletic clade despite being isolated from human subjects with asymptomatic and symptomatic human giardiasis. Using a metagenomic shotgun sequencing approach, we observed that infected individuals with asymptomatic and symptomatic giardiasis represented distinctive microbial diversity profiles, and that both were distinguishable from the profiles of healthy volunteers. These findings identify a potential association between host microbiome disparity with the development of clinical disease during human giardiasis, and may provide insights into the mechanisms by which the parasite induces pathological changes in the gut. These observations may also lead to the development of novel selective therapeutic targets for preventing human enteric microbial infections.

Sections du résumé

BACKGROUND BACKGROUND
The mechanisms underlying the clinical outcome disparity during human infection with Giardia duodenalis are still unclear. In recent years, evidence has pointed to the roles of host factors as well as parasite's genetic heterogeneity as major contributing factors in the development of symptomatic human giardiasis. However, it remains contested as to how only a small fraction of individuals infected with G. duodenalis develop clinical gastrointestinal manifestations, whereas the majority of infected individuals remain asymptomatic. Here, we demonstrate that diversity in the fecal microbiome correlates with the clinical outcome of human giardiasis.
METHODS METHODS
The genetic heterogeneity of G. duodenalis clinical isolates from human subjects with asymptomatic and symptomatic giardiasis was determined using a multilocus analysis approach. We also assessed the genetic proximity of G. duodenalis isolates by constructing phylogenetic trees using the maximum likelihood. Total genomic DNA (gDNA) from fecal specimens was utilized to construct DNA libraries, followed by performing paired-end sequencing using the HiSeq X platform. The Kraken2-generated, filtered FASTQ files were assigned to microbial metabolic pathways and functions using HUMAnN 3.04 and the UniRef90 diamond annotated full reference database (version 201901b). Results from HUMAnN for each sample were evaluated for differences among the biological groups using the Kruskal-Wallis non-parametric test with a post hoc Dunn test.
RESULTS RESULTS
We found that a total of 8/11 (72.73%) human subjects were infected with assemblage A (sub-assemblage AII) of G. duodenalis, whereas 3/11 (27.27%) human subjects in the current study were infected with assemblage B of the parasite. We also found that the parasite's genetic diversity was not associated with the clinical outcome of the infection. Further phylogenetic analysis based on the tpi and gdh loci indicated that those clinical isolates belonging to assemblage A of G. duodenalis subjects clustered compactly together in a monophyletic clade despite being isolated from human subjects with asymptomatic and symptomatic human giardiasis. Using a metagenomic shotgun sequencing approach, we observed that infected individuals with asymptomatic and symptomatic giardiasis represented distinctive microbial diversity profiles, and that both were distinguishable from the profiles of healthy volunteers.
CONCLUSIONS CONCLUSIONS
These findings identify a potential association between host microbiome disparity with the development of clinical disease during human giardiasis, and may provide insights into the mechanisms by which the parasite induces pathological changes in the gut. These observations may also lead to the development of novel selective therapeutic targets for preventing human enteric microbial infections.

Identifiants

pubmed: 37464386
doi: 10.1186/s13071-023-05821-1
pii: 10.1186/s13071-023-05821-1
pmc: PMC10354925
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

239

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM113123
Pays : United States
Organisme : NIH HHS
ID : NIH/NIGMSP20GM113123
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Infect Immun. 2016 Sep 19;84(10):2853-60
pubmed: 27456829
Infect Immun. 2009 Feb;77(2):685-93
pubmed: 19047410
J Parasit Dis. 2021 Sep;45(3):655-663
pubmed: 34475646
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):81-3
pubmed: 17943329
Nature. 2019 Dec;576(7785):143-148
pubmed: 31776512
PLoS One. 2015 Dec 07;10(12):e0143981
pubmed: 26641082
Med Sci Monit. 2015 Feb 18;21:526-32
pubmed: 25689970
Pathogens. 2021 Feb 14;10(2):
pubmed: 33672794
Virulence. 2018 Dec 31;9(1):879-894
pubmed: 29726306
PLoS Negl Trop Dis. 2021 Jan 19;15(1):e0008987
pubmed: 33465074
Parasitology. 2021 Apr;148(5):550-561
pubmed: 32981546
Int J Parasitol. 2008 Feb;38(2):259-64
pubmed: 17854810
Infect Genet Evol. 2013 Jul;17:269-76
pubmed: 23624189
Parasitology. 2009 Sep;136(10):1161-8
pubmed: 19631012
Clin Microbiol Rev. 2011 Jan;24(1):110-40
pubmed: 21233509
Infect Genet Evol. 2014 Apr;23:7-12
pubmed: 24462623
Am J Physiol Gastrointest Liver Physiol. 2016 Apr 15;310(8):G574-85
pubmed: 26744469
Parasit Vectors. 2015 Sep 04;8:444
pubmed: 26338670
Elife. 2021 May 04;10:
pubmed: 33944776
Biochemistry. 1999 Feb 23;38(8):2542-50
pubmed: 10029549
Clin Microbiol Rev. 2001 Jul;14(3):447-75
pubmed: 11432808
Int J Parasitol. 1990 Aug;20(5):697-9
pubmed: 2228433
Int J Mol Sci. 2021 Jul 12;22(14):
pubmed: 34299071
Infect Genet Evol. 2018 Dec;66:335-345
pubmed: 29225147
Nature. 2020 May;581(7809):475-479
pubmed: 32461639
Infect Immun. 2004 Jun;72(6):3536-42
pubmed: 15155662
Crit Rev Microbiol. 2002;28(2):123-47
pubmed: 12109771
Am J Trop Med Hyg. 1989 Nov;41(5):512-20
pubmed: 2554737
Infect Immun. 2013 Jul;81(7):2309-17
pubmed: 23589577
Front Immunol. 2022 Feb 17;13:817468
pubmed: 35250996
Scand J Gastroenterol. 1997 Jan;32(1):48-51
pubmed: 9018766
Int J Parasitol. 2005 Feb;35(2):207-13
pubmed: 15710441
Mucosal Immunol. 2013 Mar;6(2):369-78
pubmed: 22910215
J Infect Dis. 2005 Dec 15;192(12):2171-3
pubmed: 16288384
Front Immunol. 2019 Nov 26;10:2718
pubmed: 31849941
J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S73-7
pubmed: 18336669
J Immunol. 2000 Feb 1;164(3):1478-87
pubmed: 10640765
Emerg Infect Dis. 2003 Nov;9(11):1444-52
pubmed: 14718089
Sci Rep. 2021 Sep 22;11(1):18842
pubmed: 34552170
J Infect Dis. 2000 Apr;181(4):1510-2
pubmed: 10751141
J Immunol. 2011 Oct 1;187(7):3769-75
pubmed: 21873528
Infect Genet Evol. 2004 Jun;4(2):125-30
pubmed: 15157630
J Infect Dev Ctries. 2016 Sep 30;10(9):1035-1041
pubmed: 27694739
Emerg Infect Dis. 2011 Jan;17(1):7-15
pubmed: 21192848
J Gastroenterol Hepatol. 2000 Mar;15(3):290-3
pubmed: 10764030
Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15687-92
pubmed: 17030798
Gastroenterology. 1995 Sep;109(3):766-73
pubmed: 7657104
Parasitol Res. 2021 Dec;120(12):4199-4218
pubmed: 34623485
Biomed Pharmacother. 2018 May;101:563-571
pubmed: 29514129
Sci Rep. 2019 Dec 30;9(1):20328
pubmed: 31889073
MMWR Surveill Summ. 2012 Sep 7;61(5):13-23
pubmed: 22951494
Plant Physiol. 2003 Apr;131(4):1808-15
pubmed: 12692340
Eur J Clin Microbiol Infect Dis. 2015 Aug;34(8):1573-81
pubmed: 25939803
Parasitology. 2018 Oct;145(12):1577-1587
pubmed: 29554992
Genomics. 2022 Sep;114(5):110462
pubmed: 35998788
Parasit Vectors. 2020 Apr 19;13(1):200
pubmed: 32306993
Gut Pathog. 2013 Aug 30;5(1):26
pubmed: 23991642
J Microbiol Methods. 2017 Oct;141:35-41
pubmed: 28716658
Microbes Infect. 2015 Jun;17(6):462-7
pubmed: 25797399
Infect Immun. 2017 May 23;85(6):
pubmed: 28396324
PLoS One. 2020 Oct 1;15(10):e0240119
pubmed: 33002078
Infect Immun. 2000 Jun;68(6):3412-8
pubmed: 10816492
Ann Trop Med Parasitol. 2008 Oct;102(7):585-95
pubmed: 18817599
Neurobiol Aging. 2020 Aug;92:114-134
pubmed: 32417748
mSphere. 2020 Aug 5;5(4):
pubmed: 32759335
Am J Trop Med Hyg. 1994 Jun;50(6):705-13
pubmed: 8024063
Acta Trop. 2007 May;102(2):92-9
pubmed: 17498637
Microbes Infect. 2016 Nov;18(11):687-695
pubmed: 27401766
Front Plant Sci. 2020 Dec 17;11:589026
pubmed: 33408729
J Med Microbiol. 2000 Mar;49(3):209-215
pubmed: 10707940
Parasitol Res. 2016 Nov;115(11):4189-4198
pubmed: 27473837
Clin Infect Dis. 2021 Mar 1;72(5):764-770
pubmed: 32047932
Cell. 2013 Jul 18;154(2):403-15
pubmed: 23870128
Int J Parasitol. 2000 Nov;30(12-13):1259-67
pubmed: 11113253
Int J Parasitol. 2002 Jul;32(8):1023-30
pubmed: 12076631
J Immunol. 2006 Jan 1;176(1):516-21
pubmed: 16365445
PLoS Negl Trop Dis. 2021 Mar 25;15(3):e0009277
pubmed: 33764999
Probiotics Antimicrob Proteins. 2020 Mar;12(1):271-279
pubmed: 30610454
Front Med (Lausanne). 2022 Oct 05;9:976956
pubmed: 36275791
Front Microbiol. 2018 Jan 31;8:2707
pubmed: 29472895
Infect Immun. 2002 Jul;70(7):3673-80
pubmed: 12065509
PLoS Negl Trop Dis. 2017 Dec 11;11(12):e0006120
pubmed: 29228011
Int J Parasitol. 2017 May;47(6):311-326
pubmed: 28237889
Exp Parasitol. 2010 Nov;126(3):292-7
pubmed: 20599999

Auteurs

Brett A McGregor (BA)

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA.

Elham Razmjou (E)

Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Hossein Hooshyar (H)

Department of Medical Parasitology and Mycology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

Drew R Seeger (DR)

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA.

Svetlana A Golovko (SA)

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA.

Mikhail Y Golovko (MY)

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA.

Steven M Singer (SM)

Department of Biology, Georgetown University, Washington, DC, USA.

Junguk Hur (J)

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA.

Shahram Solaymani-Mohammadi (S)

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA. shahram.solaymani@und.edu.
Laboratory of Mucosal Immunology, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA. shahram.solaymani@und.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH